Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.–(BUSINESS WIRE)– Concert
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will
present a corporate overview at the following upcoming investor
conferences:

• The Wells Fargo Securities 2016 Healthcare Conference on September 8,
  2016 at 2:20 p.m. EDT in Boston, MA; and
• The Ladenburg Thalmann 2016 Healthcare Conference on September 27,
  2016 at 9:30 a.m. EDT in New York, NY.

A live webcast of Concert’s presentations at these conferences may be
accessed in the Investors
section of the Company’s website at www.concertpharma.com.
Please log on to the Concert website approximately 15 minutes prior to
the scheduled webcast to ensure adequate time for any software downloads
that may be required. A replay of the webcast will be available on
Concert’s website for 2 weeks following each presentation.

Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company’s
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, central nervous systems (CNS) disorders, as
well as autoimmune and inflammatory diseases. For more information
please visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005054/en/